Lee Financial CO Halozyme Therapeutics, Inc. Transaction History

Lee Financial CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $2,300 - $3,899	70 Added 28.0%	320 $12,000
Q4 2022 Feb 09, 2023	BUY	$40.06 - $59.44 $2,403 - $3,566	60 Added 31.58%	250 $14,000
Q3 2022 Nov 01, 2022	BUY	$38.53 - $51.78 $7,320 - $9,838	190 New	190 $8,000
Q1 2022 May 11, 2022	SELL	$31.97 - $41.06 $1,374 - $1,765	-43 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$31.82 - $40.75 $1,368 - $1,752	43 New	43 $2,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Lee Financial CO, based on Form 13F filings with the SEC.

Stay updated on Lee Financial CO with notifications on news.